• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Pharmaceutics. 2023 Jan 18;15(2):323. doi: 10.3390/pharmaceutics15020323.ABSTRACTDyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis of lipid-lowering therapy. Nevertheless, these drugs are often insufficient due to their side effects and restrictive criteria for achieving the recommended LDL-C values. Even the addition of other drugs, i.e., ezetimibe, does not help one achieve th...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Łukasz Wołowiec Joanna Osiak Anna Wo łowiec Aleksandra Wijata El żbieta Grześk Mariusz Kozakiewicz Joanna Banach Alicja Nowaczyk Jacek Nowaczyk Grzegorz Grze śk Source Type: research

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Curr Atheroscler Rep. 2022 Jul 29. doi: 10.1007/s11883-022-01057-z. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Since the discovery of PCSK9 in 2003, this proprotein convertase was shown to target specific receptors for degradation in endosomes/lysosomes, including LDLR and other family members and hence to enhance the levels of circulating LDL-cholesterol (LDLc). Accordingly, inhibitors of PCSK9, including monoclonal antibodies blocking its circulating activity and siRNA silencers of its hepatic expression, are now used in clinics worldwide to treat hypercholesterolemia patients effectively and safely in combination ...
Source: Atherosclerosis - July 29, 2022 Category: Cardiology Authors: Nabil G Seidah Damien Gar çon Source Type: research

New Strategies for Lowering Low-Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention
AbstractPurpose of ReviewThe primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on optimizing cardiovascular health and appropriate pharmacotherapy, a mainstay of which is low-density lipoprotein cholesterol (LDL-C) lowering. Typically, statin therapy remains the first-line approach. Advances in technology and understanding of lipid metabolism have facilitated the development of several novel therapeutic targets and medications within the last decade. This review focuses on medications recently approved by the US Food and Drug Administration (FDA) for the reduction of LDL-C and ASCVD ...
Source: Current Cardiovascular Risk Reports - June 25, 2022 Category: Cardiology Source Type: research

Cost-benefit analysis of new lipid-lowering agents
Herz. 2022 Apr 25. doi: 10.1007/s00059-022-05116-8. Online ahead of print.ABSTRACTPatients with atherosclerotic cardiovascular disease have a high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a central and direct cause of this, with a frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when consideri...
Source: Atherosclerosis - April 25, 2022 Category: Cardiology Authors: Christopher Blaum Natalie Arnold Christoph Waldeyer Source Type: research

New Trends in Dyslipidemia Treatment.
Abstract Dyslipidemia is one of the most important risk factors for cardiovascular (CV) disease. Statin therapy has dramatically improved CV outcomes and is the backbone of current lipid-lowering therapy, but despite well-controlled low-density lipoprotein cholesterol (LDL-C) levels through statin administration, up to 40% patients still experience CV disease. New therapeutic agents to tackle such residual cholesterol risk by lowering not only LDL-C but triglycerides (TG), TG-rich lipoproteins (TRL), or lipoprotein(a) (Lp(a)) are being introduced. Ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) mo...
Source: Circulation Journal - November 12, 2020 Category: Cardiology Authors: Jang AY, Lim S, Jo SH, Han SH, Koh KK Tags: Circ J Source Type: research

PCSK9 inhibition in the management of familial hypercholesterolemia.
Abstract Familial hypercholesterolemia (FH) is a frequent hereditary metabolic disease characterized by high serum low-density lipoprotein (LDL) cholesterol concentration and premature atherosclerotic cardiovascular disease (ASCVD). The discovery of the LDL receptor as one of the causative genes of FH enabled us to understand the pathophysiology of FH and paved the way for developing statins. Similar to LDL receptor, discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) also created an opportunity for developing its inhibitors. Since PCSK9 degrades LDL receptor protein, inhibiting PCSK9 will be an eff...
Source: Journal of Cardiology - August 4, 2017 Category: Cardiology Authors: Ogura M Tags: J Cardiol Source Type: research